2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Townsend, D. M. Articles by Hanigan, M. H. Search for Related Content PubMed PubMed Citation Articles by Townsend, D. M. Articles by Hanigan, M. H.

Metabolism of Cisplatin to a Nephrotoxin in Proximal Tubule Cells

Danyelle M. Townsend^*, Mei Deng^*, Lei Zhang, Maia G. Lapus and Marie H. Hanigan

*Department of Cell Biology, University of Virginia Health Sciences Center, Charlottesville, Virginia; and Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Correspondence to Dr. Marie H. Hanigan, Biomedical Research Center Room 264, 975 N.E. 10th Street, Oklahoma City, Oklahoma 73104. Phone: 405-271-3832; Fax: 405-271-3813;

ABSTRACT. Cisplatin, a commonly used chemotherapeutic agent, is nephrotoxic. The mechanism by which cisplatin selectively kills the proximal tubule cells was heretofore unknown. Recent studies in mice and rats have shown that the nephrotoxicity of cisplatin can be blocked by acivicin or (aminooxy)acetic acid, the same enzyme inhibitors that block the metabolic activation of a series of nephrotoxic halogenated alkenes. In this study, it was hypothesized that cisplatin is activated in the kidney to a toxic metabolite through the same pathway that has been shown to activate the halogenated alkenes. This activation begins with the formation of a glutathione-conjugate that is metabolized to a cysteinyl-glycine-conjugate, to a cysteine-conjugate, and finally to a reactive thiol. In this study, a protocol was developed in which confluent monolayers of LLC-PK₁ cells were exposed to clinically relevant concentrations of cisplatin or cisplatin-conjugate for 3 h. Cell viability was assayed at 72 h. The role of gamma-glutamyl transpeptidase (GGT) and cysteine-S-conjugate beta-lyase in the metabolism of each of the cisplatin-conjugates was investigated. Pre-incubation of cisplatin with glutathione, cysteinyl-glycine, or N-acetyl-cysteine to allow for the spontaneous formation of cisplatin-conjugates increased the toxicity of cisplatin toward LLC-PK₁ cells. Inhibition of GGT activity showed that GGT was necessary only for the toxicity of the cisplatin-glutathione-conjugate. Inhibition of cysteine-S-conjugate beta-lyase reduced the toxicity of each of the cisplatin-conjugates. These data demonstrate that metabolism of cisplatin in proximal tubule cells is required for its nephrotoxicity. The elucidation of this pathway provides new targets for the inhibition of cisplatin nephrotoxicity. E-mail: marie-hanigan@ouhsc.edu

This article has been cited by other articles:

				T. Uehara, T. Miyoshi, N. Tsuchiya, K. Masuno, M. Okada, S. Inoue, M. Torii, J. Yamate, and T. Maruyama Comparative analysis of gene expression between renal cortex and papilla in nedaplatin-induced nephrotoxicity in rats Human and Experimental Toxicology, October 1, 2007; 26(10): 767 - 780. [Abstract] [PDF]

				G. Ciarimboli, T. Ludwig, D. Lang, H. Pavenstadt, H. Koepsell, H.-J. Piechota, J. Haier, U. Jaehde, J. Zisowsky, and E. Schlatter Cisplatin Nephrotoxicity Is Critically Mediated via the Human Organic Cation Transporter 2 Am. J. Pathol., December 1, 2005; 167(6): 1477 - 1484. [Abstract] [Full Text] [PDF]

				A. Nanez, N. F. Alejandro, M. H. Falahatpisheh, J. K. Kerzee, J. B. Roths, and K. S. Ramos Disruption of glomerular cell-cell and cell-matrix interactions in hydrocarbon nephropathy Am J Physiol Renal Physiol, December 1, 2005; 289(6): F1291 - F1303. [Abstract] [Full Text] [PDF]

				F. Yu, J. Megyesi, R. L. Safirstein, and P. M. Price Identification of the functional domain of p21WAF1/CIP1 that protects cells from cisplatin cytotoxicity Am J Physiol Renal Physiol, September 1, 2005; 289(3): F514 - F520. [Abstract] [Full Text] [PDF]

				J. Min, P. P. Van Veldhoven, L. Zhang, M. H. Hanigan, H. Alexander, and S. Alexander Sphingosine-1-Phosphate Lyase Regulates Sensitivity of Human Cells to Select Chemotherapy Drugs in a p38-Dependent Manner Mol. Cancer Res., May 1, 2005; 3(5): 287 - 296. [Abstract] [Full Text] [PDF]

				M. H. Hanigan, M. Deng, L. Zhang, P. T. Taylor Jr., and M. G. Lapus Stress response inhibits the nephrotoxicity of cisplatin Am J Physiol Renal Physiol, January 1, 2005; 288(1): F125 - F132. [Abstract] [Full Text] [PDF]

				H. Kawai, W. Sato, Y. Yuzawa, T. Kosugi, S. Matsuo, Y. Takei, K. Kadomatsu, and T. Muramatsu Lack of the Growth Factor Midkine Enhances Survival against Cisplatin-Induced Renal Damage Am. J. Pathol., November 1, 2004; 165(5): 1603 - 1612. [Abstract] [Full Text] [PDF]

				P. M. Price, R. L. Safirstein, and J. Megyesi Protection of renal cells from cisplatin toxicity by cell cycle inhibitors Am J Physiol Renal Physiol, February 1, 2004; 286(2): F378 - F384. [Abstract] [Full Text] [PDF]

				L. Zhang and M. H. Hanigan Role of Cysteine S-Conjugate {beta}-Lyase in the Metabolism of Cisplatin J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 988 - 994. [Abstract] [Full Text] [PDF]

				D. M. Townsend, J. A. Marto, M. Deng, T. J. Macdonald, and M. H. Hanigan HIGH PRESSURE LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY CHARACTERIZATION OF THE NEPHROTOXIC BIOTRANSFORMATION PRODUCTS OF CISPLATIN Drug Metab. Dispos., June 1, 2003; 31(6): 705 - 713. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673